This study used both pharmacological and molecular approaches to investigate the hypothesis that the efficacy of free IPA‐3 and SSL‐IPA‐3 is dependent on the expression of PAK‐1 in diverse cancer cells, including prostate and breast cancer, as well as melanoma cells. The gene discussed is PAK1; the disease is breast cancer.